Inclusion Criteria:

• 1. Patients with a diagnosis of moderate to severe plaque type psoriasis confirmed by the principal investigator. Moderate to severe psoriasis will be defined as affected BSA ≥3%. Healthy controls will be age and sex matched (see below) subjects with no prior or current history of psoriasis.
• 2. Are at least 18 years of age
• 3. Psoriasis has been stable over the last 3 months
• 4. Psoriasis is either untreated or treated only with topicals at the current time (see exclusion criteria for washout times)
• 5. Subjectively reported poor sleep quality using the Pittsburg Sleep Quality Index (PSQI) (defined as a global score \>5)
• 6. Fluent in English
• 7. Demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent

Exclusion Criteria:

• 1. Patients with guttate, erythrodermic, or pustular psoriasis subtypes
• 2. Having a previous diagnosis of obstructive sleep apnea (OSA) or another medically defined sleep disorder or fall into the intermediate or high-risk groups for having OSA as calculated by the STOP-BANG questionnaire
• 3. Subjects who have used the following treatments for psoriasis: phototherapy (UVB) in the last 2 weeks, photochemotherapy (PUVA) in the last 4 weeks, oral systemic treatments in the last 4 weeks, biologic immunomodulating agents in the last 12 weeks, or have had exposure to any other investigational drug/device within 30 days prior to study entry
• 4. Subjects who have used any over the counter or prescription sleep aids within five half-lives of the agent in question.